NHL Morning Coffee Headlines – September 4, 2018
Latest on Carey Price, Nate Schmidt, Mikkel Boedker and more in your NHL morning coffee headlines.
MONTREAL GAZETTE: With defenseman Shea Weber sidelined until January and the Canadiens still carrying a pop-gun offense, goaltender Carey Price must be at his best if they’re to have any hope of reaching the playoffs next spring.
SPECTOR’S NOTE: Price had the worst performance of his career last season, in part because of the Canadiens’ weaknesses as well as injury and chronic fatigue syndrome. In the past, he’s been able to bounce back from a lousy season. If he can do it again in 2018-19, the Habs might have a shot at reaching the postseason, though he probably won’t have enough left to carry them beyond the opening round.
LAS VEGAS REVIEW-JOURNAL: Ed Graney believes the 20-game suspension received by Golden Knights defenseman Nate Schmidt illustrates how laughable the NHL’s drug-testing program is compared to other pro sports leagues. He cites in part the lack of transparency on both sides over the process and the substance used.
SPECTOR’S NOTE: Unless one of the league’s biggest stars ends up in a situation similar to Schmidt’s, I doubt we’ll see any clarity over the league’s drug-testing policies.
OTTAWA SUN: Winger Mikkel Boedker is looking forward to playing for a Canadian team for the first time in his NHL career. Boedker, who previously played with the Arizona Coyotes and San Jose Sharks, was acquired by the Senators from the Sharks in a trade this past June. Despite the Senators’ struggles last season, Boedker believes they’re “about to turn the ship around.”
SPECTOR’S NOTE: Boedker has considerable play-making skills but his production tends to be inconsistent. A career year on his part could help the Senators rebound this season.
THE ATHLETIC: Boston Bruins defenseman Brandon Carlo hopes to improve his confidence entering his third NHL season. After a promising rookie campaign his play slipped a bit last season.